Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Novartis Ag, Dana Farber Cancer Inst IncfiledCriticalHarvard College
Priority claimed from PCT/US2015/012754external-prioritypatent/WO2015112900A1/fr
Publication of MA39208A1publicationCriticalpatent/MA39208A1/fr
Publication of MA39208B1publicationCriticalpatent/MA39208B1/fr
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
L'invention concerne des molécules d'anticorps qui se lient spécifiquement à pd-1 les molécules d'anticorps anti-pd-1 peuvent être utilisées pour traiter, prévenir et/ou diagnostiquer des états ou troubles cancéreux ou infectieux.
MA39208A2014-01-242015-01-23Molécules d'anticorps anti-pd-1 et leurs utilisations
MA39208B1
(fr)